#clinical trial — Wednesday, September 30, 2026 (2 items)
| 2 | ℹ |
8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.
(linkinghub.elsevier.com)
|
The Lancet 2026-09-30 | #hepatitis c #clinical trial #antiviral #treatment #viremia | |
| 0 | ℹ |
Efficacy and Safety of P-CABs-Based Bismuth Quadruple Therapy for First-line Helicobacter pylori Eradication: A Real-World Evidence Study.
(linkinghub.elsevier.com)
|
International Journal of Antimicrobial Agents 2026-09-30 | #helicobacter pylori #eradication #amr #clinical trial #gastroenterology |